ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO461

High Effluent Lactic Acid Levels Predict the Adverse Outcomes of Peritoneal Dialysis-Associated Peritonitis: A New Role for an Old Marker

Session Information

  • Home Dialysis - 2
    October 26, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

  • Yu, Xiao, The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, China
  • Ma, Ying, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Background

Peritonitis remains the major complication of peritoneal dialysis(PD). Acute inflammation promotes glycolysis and increases the production of lactic acid by increasing the NADH-NAD+ ratio. The role of monitoring effluent lactic acid levels during treatment of peritoneal dialysis-associated peritonitis(PDAP) deserves attention.

Methods

We retrospectively collected effluent and serum lactic acid levels, and other laboratory and clinical characteristics, as well as treatment outcomes of PDAP occurred between November 2022 and October 2023. Adverse outcomes of PDAP were defined as no cure, including recurrent, relapse, catheter removal, transfer to hemodialysis and death. According to treatment outcomes, PDAP episodes were divided into cure group and no cure group. Characteristics at the beginning of PDAP were compared between the 2 groups. Factors associated with clinical outcome were analyzed using logistic regression modeling.

Results

Totally, 80 PDAP episodes were recorded in 67 PD patients. Their baseline average age was 52.4±13.8 years old, among which 64.2% were men. As for the clinical outcomes of the PDAP, 60 episodes were cured, while 20 episodes experienced adverse outcomes (no cure), among which relapse was the leading one (n=12, 15.0%), followed by catheter removal. No difference was observed in age, gender, Charlson’s Comorbidity Index, blood pressure, BMI, PD duration, peritoneal membrane transport type or Kt/V microbiologic cause between cure group and no cure group. Effluent lactic acid levels was significantly higher in no cure group[7.95(6.43,12.1) Vs 6.45(3.13,8.9), p=0.006], accompanied by a higher Day-5 effluent WCC. Multiple Logistic regression analysis showed higher effluent lactic acid levels was the independent risk factors for peritonitis adverse outcomes(odds ratio(OR)=0.822, p=0.012). ROC analyses of effluent lactic acid levels yielded a moderate discriminative capacity for adverse outcomes (area under curve(AUC)=0.71, p=0.006). The threshold values with the highest Youden’s index were 5.25 mg/L (sensitivity=100%, specificity=45%). Calibration for the ROC curve of effluent lactic acid concentration in diagnosing adverse outcome of PDAP was 0.291(Hosmer-Lemeshow goodness-of-fit test:x2=13.667, p=0.091).

Conclusion

Higher effluent lactic acid levels could predict adverse outcome of PDAP independently.